BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 1974727)

  • 1. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.
    Cooley TP; Kunches LM; Saunders CA; Perkins CJ; Kelley SL; McLaren C; McCaffrey RP; Liebman HA
    Rev Infect Dis; 1990; 12 Suppl 5():S552-60. PubMed ID: 1974727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center.
    Valentine FT; Seidlin M; Hochster H; Laverty M
    Rev Infect Dis; 1990; 12 Suppl 5():S534-9. PubMed ID: 1974725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles.
    Yarchoan R; Mitsuya H; Pluda JM; Marczyk KS; Thomas RV; Hartman NR; Brouwers P; Perno CF; Allain JP; Johns DG
    Rev Infect Dis; 1990; 12 Suppl 5():S522-33. PubMed ID: 1974724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
    Cooley TP; Kunches LM; Saunders CA; Ritter JK; Perkins CJ; McLaren C; McCaffrey RP; Liebman HA
    N Engl J Med; 1990 May; 322(19):1340-5. PubMed ID: 2139174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex.
    Dolin R; Lambert JS; Morse GD; Reichman RC; Plank CS; Reid J; Knupp C; McLaren C; Pettinelli C
    Rev Infect Dis; 1990; 12 Suppl 5():S540-9; discussion S549-51. PubMed ID: 1974726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC; Martin ES
    Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
    Lambert JS; Seidlin M; Reichman RC; Plank CS; Laverty M; Morse GD; Knupp C; McLaren C; Pettinelli C; Valentine FT
    N Engl J Med; 1990 May; 322(19):1333-40. PubMed ID: 2139173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients.
    Rozencweig M; McLaren C; Beltangady M; Ritter J; Canetta R; Schacter L; Kelley S; Nicaise C; Smaldone L; Dunkle L
    Rev Infect Dis; 1990; 12 Suppl 5():S570-5. PubMed ID: 2166965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT).
    Moyle GJ; Nelson MR; Hawkins D; Gazzard BG
    Q J Med; 1993 Mar; 86(3):155-63. PubMed ID: 8387218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
    Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B
    AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine.
    Kieburtz KD; Seidlin M; Lambert JS; Dolin R; Reichman R; Valentine F
    J Acquir Immune Defic Syndr (1988); 1992; 5(1):60-4. PubMed ID: 1346633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Didanosine: long-term follow-up of patients in a phase 1 study.
    Lambert JS; Seidlin M; Valentine FT; Reichman RC; Dolin R
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S40-5. PubMed ID: 8093846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex.
    Yarchoan R; Pluda JM; Thomas RV; Mitsuya H; Brouwers P; Wyvill KM; Hartman N; Johns DG; Broder S
    Lancet; 1990 Sep; 336(8714):526-9. PubMed ID: 1975038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.
    Butler KM; Husson RN; Balis FM; Brouwers P; Eddy J; el-Amin D; Gress J; Hawkins M; Jarosinski P; Moss H
    N Engl J Med; 1991 Jan; 324(3):137-44. PubMed ID: 1670591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
    BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
    Gatell JM; González-Lahoz J; Clotet B; Antunes F; Kasparova L; Gil-Aguado A; Saballs P; Santamaria JM; Podzamczer D; Miro JM; Jou A; Verdejo J; Doroana M; Thomis J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2',3'-dideoxyinosine (ddI).
    Reddy MM; McKinley GF; Grieco MH
    J Clin Lab Anal; 1991; 5(6):396-8. PubMed ID: 1774603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.
    Skowron G; Bozzette SA; Lim L; Pettinelli CB; Schaumburg HH; Arezzo J; Fischl MA; Powderly WG; Gocke DJ; Richman DD; Pottage JC; Antoniskis D; McKinley GF; Hyslop NE; Ray G; Simon G; Reed N; LoFaro ML; Uttamchandani RB; Gelb LD; Sperber SJ; Murphy RL; Leedom JM; Grieco MH; Zachary J; Hirsch MS; Spector SA; Bigley J; Soo W; Merigan TC
    Ann Intern Med; 1993 Mar; 118(5):321-30. PubMed ID: 8094279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.
    McKinney RE; Maha MA; Connor EM; Feinberg J; Scott GB; Wulfsohn M; McIntosh K; Borkowsky W; Modlin JF; Weintrub P
    N Engl J Med; 1991 Apr; 324(15):1018-25. PubMed ID: 1672443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.